Jan A Staessen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3844708/publications.pdf

Version: 2024-02-01

750 papers 62,741 citations

109 h-index 229 g-index

765 all docs

765 docs citations

765 times ranked 44927 citing authors

#	Article	IF	CITATIONS
1	Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2022, 79, 241-250.	1.3	14
2	Increased Collagen Turnover Is a Feature of Fibromuscular Dysplasia and Associated With Hypertrophic Radial Remodeling: A Pilot, Urine Proteomic Study. Hypertension, 2022, 79, 93-103.	1.3	4
3	Aspirin use is associated with increased risk for incident heart failure: a patientâ€level pooled analysis. ESC Heart Failure, 2022, 9, 685-694.	1.4	10
4	The novel proteomic signature for cardiac allograft vasculopathy. ESC Heart Failure, 2022, 9, 1216-1227.	1.4	8
5	Open-Angle Glaucomatous Optic Neuropathy Is Related to Dips Rather Than Increases in the Mean Arterial Pressure Over 24-H. American Journal of Hypertension, 2022, 35, 703-714.	1.0	5
6	Dissecting the Polygenic Basis of Primary Hypertension: Identification of Key Pathway-Specific Components. Frontiers in Cardiovascular Medicine, 2022, 9, 814502.	1.1	5
7	Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. Nature Genetics, 2022, 54, 437-449.	9.4	215
8	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	2.9	7
9	Risk Stratification by Cross-Classification of Central and Brachial Systolic Blood Pressure. Hypertension, 2022, 79, 1101-1111.	1.3	19
10	Two-Year Responses of Renal Function to First Occupational Lead Exposure. Kidney International Reports, 2022, , .	0.4	3
11	Association of colorectal cancer with genetic and epigenetic variation in PEAR1â€"A population-based cohort study. PLoS ONE, 2022, 17, e0266481.	1.1	1
12	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	2.9	5
13	QTc intervals are not prolonged in former ELBW infants at pre-adolescent age. Pediatric Research, 2022, 92, 848-852.	1.1	1
14	Urinary Proteomic Profile of Arterial Stiffness Is Associated With Mortality and Cardiovascular Outcomes. Journal of the American Heart Association, 2022, 11, e024769.	1.6	9
15	Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2022, 40, 3430-3438.	0.8	29
16	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	2.0	47
17	Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. Hypertension, 2021, 77, 39-48.	1.3	24
18	Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension. Hypertension, 2021, 77, 254-264.	1.3	51

#	Article	IF	Citations
19	Diastolic left ventricular function in relation to the retinal microvascular fractal dimension in a Flemish population. Hypertension Research, 2021, 44, 446-453.	1.5	О
20	Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension, 2021, 77, 788-798.	1.3	7
21	Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan. Pharmacogenomics Journal, 2021, 21, 346-358.	0.9	15
22	Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. American Journal of Hypertension, 2021, 34, 929-938.	1.0	15
23	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	1.3	47
24	Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology. American Journal of Hypertension, 2021, 34, 669-679.	1.0	10
25	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	4
26	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	1.9	46
27	Sex differences in the longitudinal relationship of low-grade inflammation and echocardiographic measures in the Hoorn and FLEMENGHO Study. PLoS ONE, 2021, 16, e0251148.	1.1	2
28	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	2.9	37
29	Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 1549-1558.	1.3	16
30	Two-Year Responses of Heart Rate and Heart Rate Variability to First Occupational Lead Exposure. Hypertension, 2021, 77, 1775-1786.	1.3	7
31	A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine, 2021, 36, 100883.	3.2	28
32	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	1.4	11
33	Normal-tension glaucomatous optic neuropathy is related to blood pressure variability in the Maracaibo Aging Study. Hypertension Research, 2021, 44, 1105-1112.	1.5	7
34	Glomerular function in relation to fine airborne particulate matter in a representative population sample. Scientific Reports, 2021, 11, 14646.	1.6	3
35	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. Blood Pressure, 2021, 30, 269-281.	0.7	8
36	CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVIDâ€19: A potential link to molecular pathophysiology?. Proteomics, 2021, 21, e2100133.	1.3	16

#	Article	IF	Citations
37	The International Database of Central Arterial Properties for Risk Stratification: Research Objectives and Baseline Characteristics of Participants. American Journal of Hypertension, 2021, , .	1.0	6
38	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
39	Investigating the Relations Between Caffeine-Derived Metabolites and Plasma Lipids in 2 Population-Based Studies. Mayo Clinic Proceedings, 2021, 96, 3071-3085.	1.4	2
40	Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 10, 200100.	0.4	1
41	Serum and urinary biomarkers of collagen typeâ€l turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 2021, 11, e267.	1.7	10
42	Cardiac Microvascular Endothelial Cells in Pressure Overload–Induced Heart Disease. Circulation: Heart Failure, 2021, 14, e006979.	1.6	20
43	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€~OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	1.0	77
44	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. BMC Medical Research Methodology, 2021, 21, 218.	1.4	4
45	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. The Lancet Healthy Longevity, 2021, 2, e690-e703.	2.0	17
46	Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. Hypertension, 2021, 78, 1222-1231.	1.3	16
47	Two-year neurocognitive responses to first occupational lead exposure. Scandinavian Journal of Work, Environment and Health, 2021, 47, 233-243.	1.7	5
48	Commentary: "Lower is Betterâ€â€" SPRINTing to STEPping up hypertension research? An historical perspective on hypertension trials. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 11, 200122.	0.4	0
49	Electrocardiographic left ventricular hypertrophy in relation to peripheral and central blood pressure indices in a Nigerian population. Blood Pressure, 2020, 29, 39-46.	0.7	2
50	A novel urinary biomarker predicts 1-year mortality after discharge from intensive care. Critical Care, 2020, 24, 10.	2.5	16
51	Central hemodynamics in relation to low-level environmental lead exposure. Blood Pressure, 2020, 29, 157-167.	0.7	3
52	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373.	1.0	103
53	Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis—A multicentre study. EBioMedicine, 2020, 62, 103083.	2.7	10
54	Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of the American Heart Association, 2020, 9, e016009.	1.6	8

#	Article	IF	CITATIONS
55	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 579400.	1.1	2
56	Two-Year Responses of Office and Ambulatory Blood Pressure to First Occupational Lead Exposure. Hypertension, 2020, 76, 1299-1307.	1.3	5
57	Retinal and Renal Microvasculature in Relation to Central Hemodynamics in 11‥earâ€Old Children Born Preterm or At Term. Journal of the American Heart Association, 2020, 9, e014305.	1.6	5
58	Cardiovascular End Points and Mortality Are Not Closer Associated With Central Than Peripheral Pulsatile Blood Pressure Components. Hypertension, 2020, 76, 350-358.	1.3	33
59	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.5	78
60	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€oncept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723.	2.9	43
61	Interpretation of Population Health Metrics. Hypertension, 2020, 75, 603-614.	1.3	13
62	Individual participant data metaâ€analysis to examine interactions between treatment effect and participantâ€level covariates: Statistical recommendations for conduct and planning. Statistics in Medicine, 2020, 39, 2115-2137.	0.8	90
63	Home Blood Pressure as Predictor of Adverse Health Outcomes. Updates in Hypertension and Cardiovascular Protection, 2020, , 33-43.	0.1	0
64	Serum insulin levels are associated with vulnerable plaque components in the carotid artery: the Rotterdam Study. European Journal of Endocrinology, 2020, 182, 343-350.	1.9	8
65	Opportunities of Antidiabetic Drugs in Cardiovascular Medicine. Hypertension, 2020, 76, 420-431.	1.3	6
66	Urinary peptidomic biomarkers of renal function in heart transplant recipients. Nephrology Dialysis Transplantation, 2019, 34, 1336-1343.	0.4	10
67	Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension. Hypertension, 2019, 74, 776-783.	1.3	23
68	Area of the pressure-strain loop during ejection as non-invasive index of left ventricular performance: a population study. Cardiovascular Ultrasound, 2019, 17, 15.	0.5	8
69	Implementing Automated Office Blood Pressure Measurement. Hypertension, 2019, 74, 441-449.	1.3	5
70	Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA - Journal of the American Medical Association, 2019, 322, 409.	3.8	265
71	Diagnosis and Management of Resistant Hypertension. Hypertension, 2019, 74, 1064-1067.	1.3	1
72	Retinal Microvasculature in Relation to Central Hemodynamics in a Flemish Population. Hypertension, 2019, 74, 606-613.	1.3	10

#	Article	IF	CITATIONS
73	Opposing Age-Related Trends in Absolute and Relative Risk of Adverse Health Outcomes Associated With Out-of-Office Blood Pressure. Hypertension, 2019, 74, 1333-1342.	1.3	31
74	Variation of PEAR1 DNA methylation influences platelet and leukocyte function. Clinical Epigenetics, 2019, 11, 151.	1.8	25
75	Paroxysmal Hypertension Associated With Urination. Hypertension, 2019, 74, 1068-1074.	1.3	3
76	How to reliably diagnose arterial hypertension: lessons from 24 h blood pressure monitoring. Blood Pressure, 2019, 28, 93-98.	0.7	2
77	Extremely Low Birth Weight Predisposes to Impaired Renal Health: A Pooled Analysis. Kidney and Blood Pressure Research, 2019, 44, 897-906.	0.9	15
78	Renal Resistive Index Is Associated With Inactive Matrix Gla (γ arboxyglutamate) Protein in an Adult Populationâ€Based Study. Journal of the American Heart Association, 2019, 8, e013558.	1.6	5
79	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
80	Central hemodynamics in relation to blood lead in young men prior to chronic occupational exposure. Blood Pressure, 2019, 28, 279-290.	0.7	4
81	Vitamin K–Dependent Matrix Gla Protein as Multifaceted Protector of Vascular and Tissue Integrity. Hypertension, 2019, 73, 1160-1169.	1.3	33
82	Central Hemodynamics in Relation to Circulating Desphosphoâ€Uncarboxylated Matrix Gla Protein: A Population Study. Journal of the American Heart Association, 2019, 8, e011960.	1.6	14
83	The association of calcium channel blockers with βâ€cell function in type 2 diabetic patients: A crossâ€sectional study. Journal of Clinical Hypertension, 2019, 21, 638-647.	1.0	3
84	Blood Pressure Measurement and Treatment Decisions. Circulation Research, 2019, 124, 990-1008.	2.0	68
85	Heart rate variability and peripheral nerve conduction velocity in relation to blood lead in newly hired lead workers. Occupational and Environmental Medicine, 2019, 76, 382-388.	1.3	5
86	Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study. Blood Pressure, 2019, 28, 168-172.	0.7	11
87	Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomesâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 322, 2343.	3.8	1
88	Renal function in relation to low-level environmental lead exposure. Nephrology Dialysis Transplantation, 2019, 34, 941-946.	0.4	11
89	Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. European Journal of Preventive Cardiology, 2019, 26, 22-32.	0.8	23
90	Temporal changes in left ventricular longitudinal strain in general population: Clinical correlates and impact on cardiac remodeling. Echocardiography, 2019, 36, 458-468.	0.3	16

#	Article	IF	CITATIONS
91	Urinary Peptidomic Biomarker for Personalized Prevention and Treatment of Diastolic Left Ventricular Dysfunction. Proteomics - Clinical Applications, 2019, 13, 1800174.	0.8	17
92	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. Journal of the American Heart Association, 2019, 8, e010430.	1.6	5
93	Neurocognitive function in relation to blood lead among young men prior to chronic occupational exposure. Scandinavian Journal of Work, Environment and Health, 2019, 45, 298-307.	1.7	8
94	Association of pulse wave velocity with single nucleotide polymorphisms related to parathyroid hormone. Blood Pressure, 2018, 27, 222-230.	0.7	1
95	Management of a Pregnant Woman With Fibromuscular Dysplasia. Hypertension, 2018, 71, 540-547.	1.3	11
96	Flow-mediated slowing of brachial-radial pulse wave velocity: Methodological aspects and clinical determinants. Artery Research, 2018, 21, 29.	0.3	15
97	Conventional and Ambulatory Blood Pressure as Predictors of Diastolic Left Ventricular Function in a Flemish Population. Journal of the American Heart Association, 2018, 7, .	1.6	5
98	Reproducibility of Retinal Microvascular Traits Decoded by the Singapore I Vessel Assessment Software Across the Human Age Range. American Journal of Hypertension, 2018, 31, 438-449.	1.0	8
99	Ambulatory blood pressure and long-term risk for atrial fibrillation. Heart, 2018, 104, 1263-1270.	1.2	21
100	Association of office and ambulatory blood pressure with blood lead in workers before occupational exposure. Journal of the American Society of Hypertension, 2018, 12, 14-24.	2.3	14
101	The rationale and design of reduction of uncontrolled hypertension by Remote Monitoring and Telemedicine (REMOTE) study. Blood Pressure, 2018, 27, 99-105.	0.7	11
102	Letter to editor: Blood pressure, hypertension and lead exposure. Environmental Health, 2018, 17, 16.	1.7	5
103	Diagnosis and management of resistant hypertension: state of the art. Nature Reviews Nephrology, 2018, 14, 428-441.	4.1	24
104	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. Journal of the American Society of Hypertension, 2018, 12, 438-447.e4.	2.3	20
105	Resistant Hypertension. Hypertension, 2018, 71, 772-780.	1.3	0
106	Relation of Insulin Resistance to Longitudinal Changes in Left Ventricular Structure and Function in a General Population. Journal of the American Heart Association, 2018, 7, .	1.6	35
107	Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 586-596.	1.4	17
108	Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. Early Human Development, 2018, 118, 1-7.	0.8	20

#	Article	IF	CITATIONS
109	The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. Nephrology Dialysis Transplantation, 2018, 33, 514-522.	0.4	15
110	Ibuprofen exposure in early neonatal life does not affect renal function in young adolescence. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F107-F111.	1.4	10
111	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. Journal of Hypertension, 2018, 36, 221-229.	0.3	20
112	Brachial–ankle pulse wave velocity compared with mean arterial pressure and pulse pressure in risk stratification in a Chinese population. Journal of Hypertension, 2018, 36, 528-536.	0.3	21
113	ECG Voltage in Relation to Peripheral and Central Ambulatory Blood Pressure. American Journal of Hypertension, 2018, 31, 178-187.	1.0	12
114	Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. Nephrology Dialysis Transplantation, 2018, 33, 426-435.	0.4	27
115	Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. Nephrology Dialysis Transplantation, 2018, 33, 1122-1128.	0.4	33
116	Doppler indexes of left ventricular systolic and diastolic function in relation to haemodynamic load components in a general population. Journal of Hypertension, 2018, 36, 867-875.	0.3	4
117	Genome-wide association study for white coat effect in Japanese middle-aged to elderly people: The HOMED-BP study. Clinical and Experimental Hypertension, 2018, 40, 363-369.	0.5	2
118	Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study. Transplantation Direct, 2018, 4, e346.	0.8	7
119	Blood Pressure in relation to 24-Hour Urinary Sodium and Potassium Excretion in a Uruguayan Population Sample. International Journal of Hypertension, 2018, 2018, 1-10.	0.5	14
120	Prognostic Value of Masked Uncontrolled Hypertension. Hypertension, 2018, 72, 862-869.	1.3	94
121	Urinary proteomic signatures associated with \hat{l}^2 -blockade and heart rate in heart transplant recipients. PLoS ONE, 2018, 13, e0204439.	1.1	3
122	Branched-Chain Amino Acids as Critical Switches in Health and Disease. Hypertension, 2018, 72, 1012-1022.	1.3	63
123	Inactive matrix Gla protein is a novel circulating biomarker predicting retinal arteriolar narrowing in humans. Scientific Reports, 2018, 8, 15088.	1.6	17
124	Environmental exposure to lead: old myths never die. Lancet Public Health, The, 2018, 3, e362.	4.7	3
125	Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. Blood Pressure, 2018, 27, 341-350.	0.7	29
126	Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Pressure, 2018, 27, 358-367.	0.7	20

#	Article	IF	CITATIONS
127	Office blood pressure measurement in the 21st century. Journal of Clinical Hypertension, 2018, 20, 1104-1107.	1.0	28
128	Patterns of ambulatory blood pressure: clinical relevance and application. Journal of Clinical Hypertension, 2018, 20, 1112-1115.	1.0	23
129	Blood pressure measurement in special populations and circumstances. Journal of Clinical Hypertension, 2018, 20, 1122-1127.	1.0	20
130	Retinal microcirculation and leukocyte telomere length in the general population. Scientific Reports, 2018, 8, 7095.	1.6	5
131	Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS ONE, 2018, 13, e0193967.	1.1	10
132	Resistant hypertension. Kardiologia Polska, 2018, 76, 1031-1042.	0.3	6
133	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrology Dialysis Transplantation, 2017, 32, gfw239.	0.4	7 3
134	Masked hypertension: understanding its complexity. European Heart Journal, 2017, 38, ehw502.	1.0	64
135	Does Extremely Low Birth Weight Predispose to Low-Renin Hypertension?. Hypertension, 2017, 69, 443-449.	1.3	27
136	Left Ventricular Structure and Function in Relation to Environmental Exposure to Lead and Cadmium. Journal of the American Heart Association, 2017, 6, .	1.6	42
137	Outcome-Driven Thresholds for Increased Home Blood Pressure Variability. Hypertension, 2017, 69, 599-607.	1.3	65
138	Renal function in relation to sodium intake: aÂquantitative review of the literature. Kidney International, 2017, 92, 67-78.	2.6	29
139	Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure, 2017, 26, 321-331.	0.7	20
140	Prevalence, Treatment, and Control Rates of Conventional and Ambulatory Hypertension Across 10 Populations in 3 Continents. Hypertension, 2017, 70, 50-58.	1.3	56
141	Risk for Incident Heart Failure: A Subjectâ€Level Metaâ€Analysis From the Heart "OMics―in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	1.6	41
142	Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. Nature Communications, 2017, 8, 14977.	5.8	169
143	Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure, 2017, 26, 195-203.	0.7	31
144	Independent effects of blood pressure and parathyroid hormone on aortic pulse wave velocity in untreated Chinese patients. Journal of Hypertension, 2017, 35, 1841-1848.	0.3	13

#	Article	IF	Citations
145	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nature Communications, 2017, 8, 15805.	5.8	95
146	Associations of plasma uric acid and purine metabolites with blood pressure in children. Journal of Hypertension, 2017, 35, 982-993.	0.3	18
147	Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. Journal of the American Heart Association, 2017, 6, .	1.6	89
148	Reply. Journal of the American College of Cardiology, 2017, 69, 2880-2881.	1.2	2
149	Longitudinal Changes in LV Structure and Diastolic Function in Relation to Arterial Properties in GeneralÂPopulation. JACC: Cardiovascular Imaging, 2017, 10, 1307-1316.	2.3	35
150	Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography. European Radiology, 2017, 27, 3934-3941.	2.3	6
151	A Urinary Fragment of Mucin-1 Subunit $\hat{l}\pm$ Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. Kidney International Reports, 2017, 2, 811-820.	0.4	24
152	Blood Pressure Measurement Anno 2016. American Journal of Hypertension, 2017, 30, hpw148.	1.0	52
153	A population-based approach to assess the heritability and distribution of renal handling of electrolytes. Kidney International, 2017, 92, 1536-1543.	2.6	20
154	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. JAMA Internal Medicine, 2017, 177, 1498.	2.6	158
155	Post-processing reproducibility of the structural characteristics of the common carotid artery in a Flemish population. Artery Research, 2017, 19, 9.	0.3	3
156	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney International Reports, 2017, 2, 1066-1075.	0.4	77
157	Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	30
158	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.3	0
159	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	1.3	4
160	Left ventricular function in relation to chronic residential air pollution in a general population. European Journal of Preventive Cardiology, 2017, 24, 1416-1428.	0.8	35
161	PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Medical Genetics, 2017, 18, 45.	2.1	13
162	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.3	12

#	Article	IF	CITATIONS
163	Diurnal Blood Pressure Rhythmicity in Relation to Environmental and Genetic Cues in Untreated Referred Patients. Hypertension, 2017, 69, 128-135.	1.3	37
164	Genetics of ion homeostasis in MéniÃ⁻re's Disease. European Archives of Oto-Rhino-Laryngology, 2017, 274, 757-763.	0.8	20
165	Antihypertensive treatment decreases arterial stiffness at night but not during the day. Results from the Hypertension in the Very Elderly Trial. Blood Pressure, 2017, 26, 109-114.	0.7	О
166	Office and Home Blood Pressures as Determinants of Electrocardiographic Left Ventricular Hypertrophy Among Black Nigerians Compared With White Flemish. American Journal of Hypertension, 2017, 30, 1083-1092.	1.0	11
167	Cardiovascular Risk Associated With White-Coat Hypertension. Hypertension, 2017, 70, 676-682.	1.3	29
168	Catch–up growth in the first two years of life in Extremely Low Birth Weight (ELBW) infants is associated with lower body fat in young adolescence. PLoS ONE, 2017, 12, e0173349.	1,1	46
169	Prediction of acute coronary syndromes by urinary proteome analysis. PLoS ONE, 2017, 12, e0172036.	1.1	30
170	Peripheral blood mitochondrial DNA content in relation to circulating metabolites and inflammatory markers: A population study. PLoS ONE, 2017, 12, e0181036.	1.1	24
171	Urinary Proteomics in Predicting Heart Transplantation Outcomes (uPROPHET)—Rationale and database description. PLoS ONE, 2017, 12, e0184443.	1.1	9
172	Correlates of Peripheral Blood Mitochondrial DNA Content in a General Population. American Journal of Epidemiology, 2016, 183, kwv175.	1.6	91
173	Persistence of Masked Hypertension in Chinese Patients. American Journal of Hypertension, 2016, 29, 326-331.	1.0	11
174	Insulin Resistance in Relation to Lipids and Inflammation in Type-2 Diabetic Patients and Non-Diabetic People. PLoS ONE, 2016, 11, e0153171.	1.1	26
175	STK39 and WNK1 Are Potential Hypertension Susceptibility Genes in the BELHYPGEN Cohort. Medicine (United States), 2016, 95, e2968.	0.4	14
176	Doppler indexes of left ventricular systolic and diastolic function in relation to the arterial stiffness in a general population. Journal of Hypertension, 2016, 34, 762-771.	0.3	28
177	Impact and pitfalls of scaling of left ventricular and atrial structure in population-based studies. Journal of Hypertension, 2016, 34, 1186-1194.	0.3	60
178	Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€~OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	2.3	48
179	Vitamin-K-Dependent Protection of the Renal Microvasculature: Histopathological Studies in Normal and Diseased Kidneys. Pulse, 2016, 4, 85-91.	0.9	13
180	Xanthine oxidase gene variants and their association with blood pressure and incident hypertension. Journal of Hypertension, 2016, 34, 2147-2154.	0.3	30

#	Article	IF	Citations
181	Diastolic Left Ventricular Function in Relation to Circulating Metabolic Biomarkers in a General Population. Journal of the American Heart Association, 2016, 5, e002681.	1.6	16
182	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. EBioMedicine, 2016, 4, 162-169.	2.7	44
183	Relationship between office and home blood pressure with increasing age: The International Database of HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO). Hypertension Research, 2016, 39, 612-617.	1.5	18
184	Association of left ventricular structure and function with peripheral blood mitochondrial DNA content in a general population. International Journal of Cardiology, 2016, 214, 180-188.	0.8	10
185	Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation. Hypertension, 2016, 67, 1211-1217.	1.3	40
186	Genome-wide association study identifies 74 loci associated with educational attainment. Nature, 2016, 533, 539-542.	13.7	1,204
187	Renal Nerve Stimulation–Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. Hypertension, 2016, 68, 707-714.	1.3	77
188	Prevalence and Determinants of Masked Hypertension Among Black Nigerians Compared With a Reference Population. Hypertension, 2016, 67, 1249-1255.	1.3	13
189	Conventional and Ambulatory Blood Pressure as Predictors of Retinal Arteriolar Narrowing. Hypertension, 2016, 68, 511-520.	1.3	20
190	Additive Prognostic Value of Left Ventricular Systolic Dysfunction in a Population-Based Cohort. Circulation: Cardiovascular Imaging, $2016, 9, .$	1.3	73
191	Retinal microvascular diameter, a hypertension-related trait, in ECG-gated vs. non-gated images analyzed by IVAN and SIVA. Hypertension Research, 2016, 39, 886-892.	1.5	15
192	The Cardiovascular Risk of White-CoatÂHypertension. Journal of the American College of Cardiology, 2016, 68, 2033-2043.	1.2	129
193	Genetic variants linked to education predict longevity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13366-13371.	3.3	110
194	Alpha-1 antitrypsin deficiency. Journal of Hypertension, 2016, 34, 1659-1661.	0.3	2
195	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	1.3	147
196	CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study. Journal of Cardiovascular Translational Research, 2016, 9, 302-314.	1.1	68
197	Does Antihypertensive Drug Class Affect Dayâ€toâ€Day Variability of Selfâ€Measured Home Blood Pressure? The HOMEDâ€BP Study. Journal of the American Heart Association, 2016, 5, e002995.	1.6	28
198	Quality control of the blood pressure phenotype in the Gaoyou population study. Blood Pressure, 2016, 25, 162-168.	0.7	9

#	Article	IF	Citations
199	Renal glomerular dysfunction in relation to retinal arteriolar narrowing and high pulse pressure in seniors. Hypertension Research, 2016, 39, 138-143.	1.5	14
200	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. Current Hypertension Reports, 2016, 18, 6.	1.5	32
201	The Diurnal Profile of Central Hemodynamics in a General Uruguayan Population. American Journal of Hypertension, 2016, 29, 737-746.	1.0	20
202	Hypertensive Encephalopathy and Renal Failure in a Young Man. Hypertension, 2016, 67, 6-13.	1.3	3
203	A Woman With Treatment-Resistant Hypertension. Hypertension, 2016, 67, 243-250.	1.3	2
204	Blood Pressure Variability as Elusive Harbinger of Adverse Health Outcomes., 2016,, 129-148.		1
205	Incidence of nephrolithiasis in relation to environmental exposure to lead and cadmium in a population study. Environmental Research, 2016, 145, 1-8.	3.7	27
206	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. PLoS ONE, 2016, 11, e0157167.	1.1	42
207	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. PLoS ONE, 2016, 11, e0167582.	1.1	22
208	Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population. BMC Genetics, 2015, 16, 116.	2.7	12
209	Influence of the hospital environment and presence of the physician on the white-coat effect. Journal of Hypertension, 2015, 33, 2245-2249.	0.3	10
210	Heritability of ambulatory and office blood pressure in the Swiss population. Journal of Hypertension, 2015, 33, 2061-2067.	0.3	12
211	Characteristics of self-measured home blood pressure in a Nigerian urban community. Blood Pressure Monitoring, 2015, 20, 260-265.	0.4	5
212	Will Sodium Intake Reduction Improve Cardiovascular Outcomes in the General Population? A Critical Review of Current Evidence. Current Hypertension Reviews, 2015, 11, 22-29.	0.5	2
213	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378.	1.5	331
214	Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study. PLoS ONE, 2015, 10, e0141394.	1.1	40
215	Longitudinal Changes in Left Ventricular Diastolic Function in a General Population. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	44
216	Relationship between maternal gestational hypertension and home blood pressure in 7-year-old children and their mothers: Tohoku Study of Child Development. Hypertension Research, 2015, 38, 776-782.	1.5	13

#	Article	IF	CITATIONS
217	Optimal Number of Days for Home Blood Pressure Measurement. American Journal of Hypertension, 2015, 28, 595-603.	1.0	40
218	Dynamic Interaction Between Micro- and Macro-Circulation: A Concept With Feet of Clay. American Journal of Hypertension, 2015, 28, 693-694.	1.0	1
219	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 48-56.	1.4	7
220	Does blood pressure variability contribute to risk stratification? Methodological issues and a review of outcome studies based on home blood pressure. Hypertension Research, 2015, 38, 97-101.	1.5	17
221	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	13.7	1,328
222	Renal denervation in treatment-resistant hypertension: a reappraisal. Current Opinion in Pharmacology, 2015, 21, 48-52.	1.7	11
223	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	3.0	205
224	Reducing Salt Intake for Prevention of Cardiovascular Disease—Times Are Changing. Advances in Chronic Kidney Disease, 2015, 22, 108-115.	0.6	18
225	Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population. Hypertension, 2015, 66, 52-60.	1.3	33
226	Doppler Indexes of Left Ventricular Systolic and Diastolic Flow and Central Pulse Pressure in Relation to Renal Resistive Index. American Journal of Hypertension, 2015, 28, 535-545.	1.0	44
227	<i>PEAR1</i> is not a human hypertension-susceptibility gene. Blood Pressure, 2015, 24, 61-64.	0.7	7
228	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	0.7	65
229	Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension. Frontiers in Physiology, 2015, 6, 9.	1.3	12
230	Prognosis in Relation to Blood Pressure Variability. Hypertension, 2015, 65, 1170-1179.	1.3	74
231	Characteristics and Determinants of the Sublingual Microcirculation in Populations of Different Ethnicity. Hypertension, 2015, 65, 993-1001.	1.3	24
232	Strategies for Classifying Patients Based on Office, Home, and Ambulatory Blood Pressure Measurement. Hypertension, 2015, 65, 1258-1265.	1.3	46
233	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. International Journal of Cardiology, 2015, 185, 177-185.	0.8	31
234	Study for Promotion of Health in Recycling Lead – Rationale and design. Blood Pressure, 2015, 24, 147-157.	0.7	12

#	Article	IF	Citations
235	Renal denervationâ€"promising data from the DENERHTN trial. Nature Reviews Nephrology, 2015, 11, 258-260.	4.1	4
236	Design and feasibility of "PREMATurity as predictor of children's Cardiovascular–renal Health― (PREMATCH): A pilot study. Blood Pressure, 2015, 24, 275-283.	0.7	19
237	Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction. Journal of the American Society of Hypertension, 2015, 9, 975-984.e3.	2.3	16
238	Defining Thresholds for Home Blood Pressure Monitoring in Octogenarians. Hypertension, 2015, 66, 865-873.	1.3	36
239	Association of total cancer and lung cancer with environmental exposure to cadmium: the meta-analytical evidence. Cancer Causes and Control, 2015, 26, 1281-1288.	0.8	75
240	Inactive Matrix Gla-Protein Is Associated With Arterial Stiffness in an Adult Population–Based Study. Hypertension, 2015, 66, 85-92.	1.3	85
241	Inactive Matrix Gla Protein Is Causally Related to Adverse Health Outcomes. Hypertension, 2015, 65, 463-470.	1.3	84
242	Genome-wide association study of kidney function decline in individuals of European descent. Kidney International, 2015, 87, 1017-1029.	2.6	113
243	Masked Hypertension. Hypertension, 2015, 65, 16-20.	1.3	65
244	Blood Pressure in Relation to Environmental Lead Exposure in the National Health and Nutrition Examination Survey 2003 to 2010. Hypertension, 2015, 65, 62-69.	1.3	58
245	Cancer and Cadmium. , 2015, , 741-743.		0
246	Cancer and Cadmium., 2015, , 1-3.		0
247	Epidemiology of Masked and White-Coat Hypertension: The Family-Based SKIPOGH Study. PLoS ONE, 2014, 9, e92522.	1.1	56
248	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	1.3	61
249	Association of Target Organ Damage With 24-Hour Systolic and Diastolic Blood Pressure Levels and Hypertension Subtypes in Untreated Chinese. Hypertension, 2014, 63, 222-228.	1.3	41
250	Renal sympathetic denervation in the aftermath of Symplicity HTN-3. Blood Pressure, 2014, 23, 256-261.	0.7	6
251	An Unusual Cause of Mineralocorticoid Hypertension. Hypertension, 2014, 64, 689-692.	1.3	3
252	How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information?. American Journal of Hypertension, 2014, 27, 46-55.	1.0	49

#	Article	IF	Citations
253	Reference frame for home pulse pressure based on cardiovascular risk in 6470 subjects from 5 populations. Hypertension Research, 2014, 37, 672-678.	1.5	14
254	Hypertension Control in Community Health Centers Across China: Analysis of Antihypertensive Drug Treatment Patterns. American Journal of Hypertension, 2014, 27, 252-259.	1.0	31
255	Left ventricular mass in relation to midlife blood pressure. European Heart Journal, 2014, 35, 3242-3244.	1.0	1
256	Rationale and design of the Investigator-Steered Project on intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Pressure, 2014, 23, 138-146.	0.7	15
257	Risk Stratification by Self-Measured Home Blood Pressure across Categories of Conventional Blood Pressure: A Participant-Level Meta-Analysis. PLoS Medicine, 2014, 11, e1001591.	3.9	72
258	Estimation of Glomerular Filtration Rate Based on Serum Cystatin C versus Creatinine in a Uruguayan Population. International Journal of Nephrology, 2014, 2014, 1-9.	0.7	11
259	Con: Renal denervation for all resistant hypertensive patients: the Emperor's new clothes. Nephrology Dialysis Transplantation, 2014, 29, 1116-1119.	0.4	2
260	Cardiovascular risk factors among the inhabitants of an urban Congolese community: results of the VITARAA Study. IJC Metabolic & Endocrine, 2014, 4, 33-38.	0.5	4
261	Association of digital vascular function with cardiovascular risk factors: a population study. BMJ Open, 2014, 4, e004399.	0.8	16
262	Outcome-Driven Thresholds for Ambulatory Pulse Pressure in 9938 Participants Recruited From 11 Populations. Hypertension, 2014, 63, 229-237.	1.3	40
263	Reference Values and Factors Associated With Renal Resistive Index in a Family-Based Population Study. Hypertension, 2014, 63, 136-142.	1.3	97
264	Left ventricular diastolic function associated with common genetic variation in ATP12Ain a general population. BMC Medical Genetics, 2014, 15, 121.	2.1	4
265	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension, 2014, 32, 1359-1366.	0.3	758
266	Heritability and other determinants of left ventricular diastolic function in the family-based population study. Journal of Hypertension, 2014, 32, 1854-1861.	0.3	4
267	Quality of blood pressure phenotype in the Nigerian Population Research on Environment Gene and Health. Blood Pressure Monitoring, 2014, 19, 220-225.	0.4	9
268	Hyperresponders vs. nonresponder patients after renal denervation. Journal of Hypertension, 2014, 32, 2422-2427.	0.3	37
269	Quality of the blood pressure phenotype in the GEnotipo, Fenotipo y Ambiente de la hipertensi \tilde{A}^3 n arterial en UruguaY (GEFA-HT-UY) study. Blood Pressure Monitoring, 2014, 19, 339-345.	0.4	3
270	Blood Pressure Load Does Not Add to Ambulatory Blood Pressure Level for Cardiovascular Risk Stratification. Hypertension, 2014, 63, 925-933.	1.3	39

#	Article	IF	Citations
271	Letter by Jin et al Regarding Article, "Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension― Circulation, 2014, 129, e499.	1.6	4
272	Denervation of Native Kidneys in a Renal Transplant Recipient: One Swallow Does Not Make a Spring. American Journal of Hypertension, 2014, 27, 897-898.	1.0	1
273	Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease. Hypertension, 2014, 63, 475-482.	1.3	31
274	Beat-to-Beat, Reading-to-Reading, and Day-to-Day Blood Pressure Variability in Relation to Organ Damage in Untreated Chinese. Hypertension, 2014, 63, 790-796.	1.3	120
275	Blood pressure variability in risk stratification: What does it add?. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 1-8.	0.9	17
276	Prognosis of White-Coat and Masked Hypertension. Hypertension, 2014, 63, 675-682.	1.3	262
277	Gender and telomere length: Systematic review and meta-analysis. Experimental Gerontology, 2014, 51, 15-27.	1.2	394
278	Prognostic Value of Left Ventricular Diastolic Dysfunction in a General Population. Journal of the American Heart Association, 2014, 3, e000789.	1.6	95
279	Risk Stratification by Ambulatory Blood Pressure Monitoring Across JNC Classes of Conventional Blood Pressure. American Journal of Hypertension, 2014, 27, 956-965.	1.0	49
280	Systematic Review of Health Outcomes in Relation to Salt Intake Highlights the Widening Divide Between Guidelines and the Evidence. American Journal of Hypertension, 2014, 27, 1138-1142.	1.0	8
281	Renovascular Hypertension. Hypertension, 2014, 64, 1165-1168.	1.3	3
282	Setting Thresholds to Varying Blood Pressure Monitoring Intervals Differentially Affects Risk Estimates Associated With White-Coat and Masked Hypertension in the Population. Hypertension, 2014, 64, 935-942.	1.3	137
283	Age-specificity of blood-pressure-associated complications. Nature Reviews Cardiology, 2014, 11, 499-501.	6.1	6
284	Age-Specific Differences Between Conventional and Ambulatory Daytime Blood Pressure Values. Hypertension, 2014, 64, 1073-1079.	1.3	78
285	Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations. Circulation, 2014, 130, 466-474.	1.6	84
286	Left ventricular diastolic function in relation to the urinary proteome: A proof-of-concept study in a general population. International Journal of Cardiology, 2014, 176, 158-165.	0.8	44
287	The urinary proteome as correlate and predictor of renal function in a population study. Nephrology Dialysis Transplantation, 2014, 29, 2260-2268.	0.4	57
288	Thresholds for Conventional and Home Blood Pressure by Sex and Age in 5018 Participants From 5 Populations. Hypertension, 2014, 64, 695-701.	1.3	21

#	Article	IF	CITATIONS
289	Heart rate variability on antihypertensive drugs in black patients living in sub-Saharan Africa. Blood Pressure, 2014, 23, 174-180.	0.7	2
290	Metaâ€analysis of a continuous outcome combining individual patient data and aggregate data: a method based on simulated individual patient data. Research Synthesis Methods, 2014, 5, 322-351.	4.2	4
291	Risk Associated with Pulse Pressure on Out-of-Office Blood Pressure Measurement. Pulse, 2014, 2, 42-51.	0.9	7
292	Randomised Double-Blind Comparison of Placebo and Active Drugs for Effects on Risks Associated with Blood Pressure Variability in the Systolic Hypertension in Europe Trial. PLoS ONE, 2014, 9, e103169.	1.1	42
293	Renal Denervation After Symplicity HTN-3 – Back to Basics. Review of the Evidence. European Cardiology Review, 2014, 9, 110.	0.7	2
294	Outcome-Driven Thresholds for Pulse Pressure on Office and Out-of-the-Office Blood Pressure Measurement., 2014,, 447-457.		0
295	SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold?. Journal of Biomedical Research, 2014, 28, 73.	0.7	1
296	Nigerian Population Research on Environment, Gene and Health (NIPREGH) - objectives and protocol. Journal of Biomedical Research, 2014, 28, 360.	0.7	4
297	Heart â€~omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	0.7	24
298	No Support for Renal Denervation in a Meta-Analysis. Journal of the American College of Cardiology, 2013, 62, 2029-2030.	1.2	5
299	Electric Nerve Stimulation to Monitor the Efficacy of Renal Denervation. Hypertension, 2013, 61, 288-289.	1.3	6
300	Quality of Life After Renal Denervation. Hypertension, 2013, 61, e38.	1.3	2
301	Residual Effect of Renal Denervation in Patients With Truly Resistant Hypertension. Hypertension, 2013, 62, 450-452.	1.3	16
302	Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. Pharmacogenomics, 2013, 14, 1709-1721.	0.6	36
303	Central vs. peripheral blood pressure components as determinants of retinal microvessel diameters. Artery Research, 2013, 8, 35.	0.3	2
304	First-in-Man Randomized Clinical Trial of Renal Denervation for Atrial Arrhythmia Raises Concern. Journal of the American College of Cardiology, 2013, 62, e445-e446.	1.2	10
305	Sodium and Potassium and the Pathogenesis of Hypertension. Current Hypertension Reports, 2013, 15, 122-130.	1.5	37
306	Masked Hypertension in Diabetes Mellitus. Hypertension, 2013, 61, 964-971.	1.3	142

#	Article	IF	CITATIONS
307	cGMP-Dependent Protein Kinase 1 Polymorphisms Underlie Renal Sodium Handling Impairment. Hypertension, 2013, 62, 1027-1033.	1.3	10
308	Target Sequencing, Cell Experiments, and a Population Study Establish Endothelial Nitric Oxide Synthase (<i>eNOS</i>) Gene as Hypertension Susceptibility Gene. Hypertension, 2013, 62, 844-852.	1.3	48
309	Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. European Heart Journal, 2013, 34, 1095-1098.	1.0	16
310	Response to Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus: Attractive But Questionable Interpretations and Response to Is Masked Hypertension Related to Diabetes Mellitus?. Hypertension, 2013, 62, e23-5.	1.3	9
311	Sexual Dimorphism in the Transition From Masked to Sustained Hypertension in Healthy Youths. Hypertension, 2013, 62, 410-414.	1.3	48
312	Does White Coat Hypertension Require Treatment Over Age 80?. Hypertension, 2013, 61, 89-94.	1.3	67
313	Predictive power of home blood pressure and clinic blood pressure in hypertensive patients with impaired glucose metabolism and diabetes. Journal of Hypertension, 2013, 31, 1593-1602.	0.3	45
314	Renal denervation in the management of resistant hypertension. Current Opinion in Nephrology and Hypertension, 2013, 22, 511-518.	1.0	7
315	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension, 2013, 31, 1731-1768.	0.3	1,124
316	Heritability of The Retinal Microcirculation in Flemish Families. American Journal of Hypertension, 2013, 26, 392-399.	1.0	17
317	Home Blood Pressure Variability as Cardiovascular Risk Factor in the Population of Ohasama. Hypertension, 2013, 61, 61-69.	1.3	120
318	Response to HYVET Ambulatory Blood Pressure Substudy. Hypertension, 2013, 61, e43.	1.3	2
319	Left Ventricular Radial Function Associated With Genetic Variation in the cGMP-Dependent Protein Kinase. Hypertension, 2013, 62, 1034-1039.	1.3	5
320	Outcome-Driven Thresholds for Home Blood Pressure Measurement. Hypertension, 2013, 61, 27-34.	1.3	100
321	Central Systolic Augmentation Indexes and Urinary Sodium in a White Population. American Journal of Hypertension, 2013, 26, 95-103.	1.0	17
322	Risk Stratification by 24-Hour Ambulatory Blood Pressure and Estimated Glomerular Filtration Rate in 5322 Subjects From 11 Populations. Hypertension, 2013, 61, 18-26.	1.3	17
323	Metaâ€analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. Statistics in Medicine, 2013, 32, 2747-2766.	0.8	83
324	Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Review of Cardiovascular Therapy, $2013, 11, 739-749$.	0.6	25

#	Article	IF	Citations
325	Double Product Reflects the Predictive Power of Systolic Pressure in the General Population: Evidence from 9,937 Participants. American Journal of Hypertension, 2013, 26, 665-672.	1.0	37
326	Breastfeeding leads to lower blood pressure in 7-year-old Japanese children: Tohoku Study of Child Development. Hypertension Research, 2013, 36, 117-122.	1.5	33
327	White-Coat Hypertension. Hypertension, 2013, 62, 982-987.	1.3	185
328	Association of left ventricular diastolic function with systolic dyssynchrony: a population study. European Heart Journal Cardiovascular Imaging, 2013, 14, 471-479.	0.5	8
329	Cross-sectional and longitudinal assessment of arterial stiffening with age in European and Chinese populations. Frontiers in Physiology, 2012, 3, 209.	1.3	9
330	Within-Subject Blood Pressure Levelâ€"Not Variabilityâ€"Predicts Fatal and Nonfatal Outcomes in a General Population. Hypertension, 2012, 60, 1138-1147.	1.3	108
331	Blood Flow Pattern in the Middle Cerebral Artery in Relation to Indices of Arterial Stiffness in the Systemic Circulation. American Journal of Hypertension, 2012, 25, 319-324.	1.0	62
332	Association of left ventricular mass with the AGTR1 A1166C polymorphism. American Journal of Hypertension, 2012, 25, 472-478.	1.0	21
333	Averaging clinic and home measures associated with reductions in within-patient variability and may give a better indication of blood pressure control. Evidence-Based Medicine, 2012, 17, 82-83.	0.6	0
334	Prognostic Significance of Home Arterial Stiffness Index Derived From Self-Measurement of Blood Pressure: The Ohasama Study. American Journal of Hypertension, 2012, 25, 67-73.	1.0	10
335	Renal Denervation. Hypertension, 2012, 60, 596-606.	1.3	90
336	Response to Phenotyping the Microcirculation With Contrast-Enhanced Ultrasound. Hypertension, 2012, 60, .	1.3	0
337	Evaluating home blood pressure in treated hypertensives in comparison with the referential value of casual screening of blood pressure. Blood Pressure Monitoring, 2012, 17, 89-95.	0.4	8
338	Does Pseudoresistant Hypertension Attributed to White-Coat Effect Define Subjects With "Treated Normalized Hypertension?― Hypertension, 2012, 59, e43; author reply e44.	1.3	1
339	Cadmium from zinc smelter emission and variation in cancer incidence. European Journal of Cancer Prevention, 2012, 21, 497-498.	0.6	3
340	Phenotyping the Microcirculation. Hypertension, 2012, 60, 523-527.	1.3	24
341	Genomewide Association Study Using a High-Density Single Nucleotide Polymorphism Array and Case-Control Design Identifies a Novel Essential Hypertension Susceptibility Locus in the Promoter Region of Endothelial NO Synthase. Hypertension, 2012, 59, 248-255.	1.3	144
342	A family-based association test to detect gene–gene interactions in the presence of linkage. European Journal of Human Genetics, 2012, 20, 973-980.	1.4	5

#	Article	IF	CITATIONS
343	Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research, 2012, 35, 1102-1110.	1.5	157
344	Age dependency of peripheral and central systolic blood pressures: cross-sectional and longitudinal observations in a Chinese population. Hypertension Research, 2012, 35, 115-122.	1.5	29
345	Age dependency of central and peripheral systolic blood pressures: Cross-sectional and longitudinal observations in European populations. Blood Pressure, 2012, 21, 58-68.	0.7	25
346	Significance of White-Coat Hypertension in Older Persons With Isolated Systolic Hypertension. Hypertension, 2012, 59, 564-571.	1.3	177
347	Left Ventricular Structure and Function in Relation to Steroid Biosynthesis Genes in a White Population. American Journal of Hypertension, 2012, 25, 986-993.	1.0	3
348	Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. European Heart Journal, 2012, 33, 2342-2350.	1.0	79
349	Tissue Doppler indexes of left ventricular systolic function in relation to the pulsatile and steady components of blood pressure in a general population. Journal of Hypertension, 2012, 30, 403-410.	0.3	7
350	Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. Journal of Hypertension, 2012, 30, 67-74.	0.3	36
351	Central haemodynamics reveal significant potential for prevention in Black hypertensive patients born and living in sub-Saharan Africa. Artery Research, 2012, 6, 41.	0.3	1
352	Impact of Hypertension on Ventricular-Arterial Coupling and Regional Myocardial Work at Rest and during Isometric Exercise. Journal of the American Society of Echocardiography, 2012, 25, 882-890.	1.2	45
353	Secondary Prevention after Ischemic Stroke. New England Journal of Medicine, 2012, 367, 675-677.	13.9	4
354	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovascular Ultrasound, 2012, 10, 10.	0.5	68
355	Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients. Trials, 2012, 13, 59.	0.7	9
356	FTO genotype is associated with phenotypic variability of body mass index. Nature, 2012, 490, 267-272.	13.7	383
357	24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study. Hypertension Research, 2012, 35, 980-987.	1.5	120
358	The International Database of HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO): moving from baseline characteristics to research perspectives. Hypertension Research, 2012, 35, 1072-1079.	1.5	34
359	Individual patient data meta-analysis of survival data using Poisson regression models. BMC Medical Research Methodology, 2012, 12, 34.	1.4	66
360	Mother-off spring aggregation in home versus conventional blood pressure in the Tohoku Study of Child Development (TSCD). Acta Cardiologica, 2012, 67, 449-456.	0.3	10

#	Article	IF	Citations
361	Genome-Wide Association Study to Identify Common Variants Associated with Brachial Circumference: A Meta-Analysis of 14 Cohorts. PLoS ONE, 2012, 7, e31369.	1.1	3
362	Renal denervation: time to open Pandora's box. Swiss Medical Weekly, 2012, 142, w13638.	0.8	6
363	The Metabolic Syndrome and Carotid Intima-Media Thickness in Relation to the Parathyroid Hormone to 25-OH-D3 Ratio in a General Population. American Journal of Hypertension, 2011, 24, 102-109.	1.0	43
364	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertension Research, 2011, 34, 714-721.	1.5	28
365	Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 2011, 478, 103-109.	13.7	1,855
366	Assessment of peripheral vascular function with photoplethysmographic pulse amplitude. Artery Research, 2011, 5, 58.	0.3	6
367	Retinal arteriolar and venular phenotypes in a Flemish population: Reproducibility and correlates. Artery Research, 2011, 5, 72.	0.3	16
368	Determinants of arterial properties in Chinese type-2 diabetic patients compared with population-based controls. Acta Cardiologica, 2011, 66, 619-626.	0.3	2
369	Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). Acta Cardiologica, 2011, 66, 701-706.	0.3	23
370	Methodological issues in the assessment of cognitive decline in ONTARGET and TRANSCEND. Lancet Neurology, The, 2011, 10, 22-24.	4.9	5
371	Blood Pressure Loci Identified with a Gene-Centric Array. American Journal of Human Genetics, 2011, 89, 688-700.	2.6	159
372	Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials, 2011, 12, 13.	0.7	37
373	Are Retinal Microvascular Phenotypes Associated With the 1675G/A Polymorphism in the Angiotensin II Type-2 Receptor Gene?. American Journal of Hypertension, 2011, 24, 1300-1305.	1.0	8
374	Response to Referral of Women to Ambulatory Blood Pressure Monitoring. Hypertension, 2011, 57, .	1.3	0
375	Placebo-Controlled Trials of Blood Pressure–Lowering Therapies for Primary Prevention of Dementia. Hypertension, 2011, 57, e6-7.	1.3	67
376	Association of echocardiographic left ventricular structure with the ACE D/I polymorphism: a meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 243-253.	1.0	10
377	Fatal and Nonfatal Outcomes, Incidence of Hypertension, and Blood Pressure Changes in Relation to Urinary Sodium Excretion. JAMA - Journal of the American Medical Association, 2011, 305, 1777.	3.8	483
378	White-coat Hypertension on Automated Blood Pressure Measurement: Implications for Clinical Practice. The European Journal of Cardiovascular Medicine, $2011, \ldots$	1.0	0

#	Article	IF	Citations
379	Response to Letter Regarding Article, "Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease― Circulation: Cardiovascular Genetics, 2011, 4, .	5.1	2
380	Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Human Molecular Genetics, 2011, 20, 2273-2284.	1.4	168
381	Urinary Sodium Excretion and Cardiovascular Disease Mortalityâ€"Reply. JAMA - Journal of the American Medical Association, 2011, 306, 1083.	3.8	0
382	Heritability of left ventricular structure and function in Caucasian families. European Heart Journal Cardiovascular Imaging, 2011, 12, 326-332.	0.5	18
383	Maximum or Mean: That Is the Question. Hypertension, 2011, 58, e13-4; author reply e15.	1.3	1
384	How many measurements are needed to provide reliable information in terms of the ambulatory arterial stiffness index? the Ohasama study. Hypertension Research, 2011, 34, 314-318.	1.5	6
385	Ambulatory (AASI), but not home (HASI), arterial stiffness index is associated with aortic pulse wave velocity. Hypertension Research, 2011, 34, 402-403.	1.5	7
386	Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. Hypertension Research, 2011, 34, 489-495.	1.5	21
387	Ambulatory Blood Pressure Monitoring in 9357 Subjects From 11 Populations Highlights Missed Opportunities for Cardiovascular Prevention in Women. Hypertension, 2011, 57, 397-405.	1.3	111
388	Predictive Role of the Nighttime Blood Pressure. Hypertension, 2011, 57, 3-10.	1.3	482
389	Urinary nitric oxide metabolites and individual blood pressure progression to overt hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 656-663.	3.1	9
390	Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial. Blood Pressure, 2011, 20, 256-266.	0.7	10
391	Periodontal disease and hypertension: a chicken and egg story?. Journal of Hypertension, 2010, 28, 2382-2383.	0.3	4
392	From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering's legacy. Blood Pressure Monitoring, 2010, 15, 72-81.	0.4	4
393	Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. Journal of Hypertension, 2010, 28, 1366-1372.	0.3	160
394	Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?. Journal of Hypertension, 2010, 28, 1796-1803.	0.3	43
395	Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. Journal of Hypertension, 2010, 28, 2036-2045.	0.3	318
396	Response to Indices of Blood Pressure Variability and Cardiovascular Risk. Hypertension, 2010, 56, .	1.3	0

#	Article	IF	CITATIONS
397	Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial. Journal of Hypertension, 2010, 28, 865-874.	0.3	11
398	Cadmium exposure in the population: from health risks to strategies of prevention. BioMetals, 2010, 23, 769-782.	1.8	350
399	Cardiac involvement in Churg‧trauss syndrome. Arthritis and Rheumatism, 2010, 62, 627-634.	6.7	158
400	Telomere length and its associations with oxidized-LDL carotid artery distensibility and smoking. Frontiers in Bioscience - Elite, 2010, E2, 1164-1168.	0.9	53
401	Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations. Hypertension, 2010, 55, 1049-1057.	1.3	394
402	Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease. Circulation: Cardiovascular Genetics, 2010, 3, 499-506.	5.1	683
403	Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations. Hypertension, 2010, 55, 1040-1048.	1.3	258
404	Implications of Recently Published Trials of Blood Pressure–Lowering Drugs in Hypertensive or High-Risk Patients. Hypertension, 2010, 55, 819-831.	1.3	44
405	More Information on the Reproducibility of the Ambulatory Arterial Stiffness Index. American Journal of Hypertension, 2010, 23, 113-114.	1.0	6
406	Is Arterial Stiffness Related to Body Height?. Hypertension, 2010, 55, e24-5.	1.3	8
407	Association Between Left Ventricular Mass and Telomere Length in a Population Study. American Journal of Epidemiology, 2010, 172, 440-450.	1.6	53
408	Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure–Lowering Medications. Hypertension, 2010, 56, 1060-1068.	1.3	41
409	Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal, 2010, 31, 2205-2208.	1.0	31
410	Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 2: Clinical Studies. Science Translational Medicine, 2010, 2, 59ra87.	5.8	73
411	Systolic and diastolic left ventricular dysfunction: from risk factors to overt heart failure. Expert Review of Cardiovascular Therapy, 2010, 8, 251-258.	0.6	39
412	Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertension Research, 2010, 33, 757-766.	1.5	80
413	Online journals: paying or delaying?. Lancet, The, 2010, 375, 984.	6.3	0
414	Treatment of hypertension in the elderly in 2010 $\hat{a}\in$ a brief review. Expert Opinion on Pharmacotherapy, 2010, 11, 2609-2617.	0.9	5

#	Article	IF	CITATIONS
415	Steroid Biosynthesis and Renal Excretion in Human Essential Hypertension: Association With Blood Pressure and Endogenous Ouabain. American Journal of Hypertension, 2009, 22, 357-363.	1.0	40
416	Response to Determinants of the Ambulatory Arterial Stiffness Index Regression Line. Hypertension, 2009, 53, .	1.3	0
417	Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease. European Heart Journal, 2009, 30, 1164-1166.	1.0	1
418	Left ventricular structure in relation to the human SAH gene in the European Project on Genes in Hypertension. Hypertension Research, 2009, 32, 145-151.	1.5	4
419	Validation of automated oscillometric versus manual measurement of the ankle–brachial index. Hypertension Research, 2009, 32, 884-888.	1.5	36
420	Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Circulation: Heart Failure, 2009, 2, 105-112.	1.6	291
421	In-Hospital Mortality Among Black Patients Admitted for Hypertension-Related Disorders in Mbuji Mayi, Congo. American Journal of Hypertension, 2009, 22, 643-648.	1.0	31
422	Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertension Research, 2009, 32, 1032-1040.	1.5	148
423	Blood Pressure Variability Remains an Elusive Predictor of Cardiovascular Outcome. American Journal of Hypertension, 2009, 22, 3-4.	1.0	27
424	Independent Relations of Left Ventricular Structure With the 24-Hour Urinary Excretion of Sodium and Aldosterone. Hypertension, 2009, 54, 489-495.	1.3	58
425	Arterial Properties in Relation to Genetic Variations in the Adducin Subunits in a White Population. American Journal of Hypertension, 2009, 22, 21-26.	1.0	10
426	Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. Mechanisms of Ageing and Development, 2009, 130, 771-776.	2.2	54
427	Altered Molecular Weight Forms of Adiponectin in Hypertension. Journal of Clinical Hypertension, 2009, 11, 11-16.	1.0	17
428	Blood pressure as a prognostic factor after acute stroke. Lancet Neurology, The, 2009, 8, 938-948.	4.9	105
429	Association between carotid diameter and the advanced glycation endproduct Nepsilon-Carboxymethyllysine (CML). Cardiovascular Diabetology, 2009, 8, 45.	2.7	43
430	Fetuin-A and arterial stiffness in patients with normal kidney function. Regulatory Peptides, 2009, 154, 39-43.	1.9	23
431	Sex-specific relative and absolute risks associated with the conventional and ambulatory blood pressures in 9357 subjects from 11 populations. International Journal of Cardiology, 2009, 137, S21-S22.	0.8	0
432	Prognostic value of short-term blood pressure variability over 24 h in 8938 subjects from 11 populations. International Journal of Cardiology, 2009, 137, S22.	0.8	0

#	Article	IF	Citations
433	Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe Trial. International Journal of Cardiology, 2009, 137, S39-S40.	0.8	O
434	Telomere length predicts left ventricular mass in a general population. International Journal of Cardiology, 2009, 137, S82-S83.	0.8	0
435	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet, The, 2009, 374, 525-533.	6.3	391
436	Cardiovascular effects of tight versus usual blood-pressure control – Authors' reply. Lancet, The, 2009, 374, 1742.	6.3	1
437	Comments on the reproducibility of ambulatory arterial stiffness index and QRS Korotkoff delay index. Journal of Hypertension, 2009, 27, 436-437.	0.3	0
438	Ethnic differences in proximal and distal tubular sodium reabsorption are heritable in black and white populations. Journal of Hypertension, 2009, 27, 606-612.	0.3	54
439	Conventional and 24-h ambulatory blood pressure as independent predictors of elastic arterial properties. Blood Pressure Monitoring, 2009, 14, 12-19.	0.4	0
440	Sphygmomanometric and ambulatory blood pressures as forerunners of carotid and femoral intima–media thickness. Journal of Hypertension, 2009, 27, 813-821.	0.3	3
441	Left ventricular geometry and endogenous ouabain in a Flemish population. Journal of Hypertension, 2009, 27, 1884-1891.	0.3	13
442	Modulation of genetic cardiovascular risk by age and lifestyle. Current Cardiovascular Risk Reports, 2008, 2, 398-404.	0.8	2
443	Metaâ€analysis of continuous outcomes combining individual patient data and aggregate data. Statistics in Medicine, 2008, 27, 1870-1893.	0.8	222
444	Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta-Analysis—Clinical Implications. Journal of Clinical Hypertension, 2008, 10, 377-381.	1.0	34
445	Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine, 2008, 358, 1887-1898.	13.9	2,714
446	Day or night blood pressures for prognosis – Authors' reply. Lancet, The, 2008, 371, 114-115.	6.3	0
447	Left ventricular strain and strain rate in a general population. European Heart Journal, 2008, 29, 2014-2023.	1.0	188
448	Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations. Hypertension, 2008, 52, 229-235.	1.3	87
449	Is "Usual" Blood Pressure a Proxy for 24-h Ambulatory Blood Pressure in Predicting Cardiovascular Outcomes?. American Journal of Hypertension, 2008, 21, 994-1000.	1.0	18
450	Reducing blood pressure in people of different ages. BMJ: British Medical Journal, 2008, 336, 1080-1081.	2.4	5

#	Article	IF	CITATIONS
451	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. Journal of Hypertension, 2008, 26, 1505-1526.	0.3	707
452	Characterization and Functional Analyses of the Human G Protein–Coupled Receptor Kinase 4 Gene Promoter. Hypertension, 2008, 52, 737-746.	1.3	10
453	Segmental Renal Sodium Handling in Relation to the Human SAH Gene. Hypertension, 2008, 52, e12-3.	1.3	0
454	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. European Heart Journal, 2008, 30, 679-688.	1.0	66
455	Blood Pressure and Renal Sodium Handling in Relation to Genetic Variation in the <i>DRD1</i> Promoter and <i>GRK4</i> . Hypertension, 2008, 51, 1643-1650.	1.3	54
456	Spotlights on Ambulatory Measures of Arterial Stiffness. American Journal of Hypertension, 2008, 21, 368-369.	1.0	1
457	Reference Values for the Arterial Pulse Wave in Chinese. American Journal of Hypertension, 2008, 21, 668-673.	1.0	28
458	Determinants of the Ambulatory Arterial Stiffness Index in 7604 Subjects From 6 Populations. Hypertension, 2008, 52, 1038-1044.	1.3	37
459	Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension. Hypertension, 2008, 51, 55-61.	1.3	644
460	Can lowering blood pressure prevent vascular complications in patients with type 2 diabetes?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 194-195.	3.3	0
461	Wave Reflection in Systolic Hypertension: Smaller Stature, Shorter Aorta: Higher Pulse Pressure?. Hypertension, 2008, 51, e37; author reply e39-40.	1.3	1
462	Heritability and intrafamilial aggregation of arterial characteristics. Journal of Hypertension, 2008, 26, 721-728.	0.3	29
463	Effects of genetic variation in adducin on left ventricular diastolic function as assessed by tissue Doppler imaging in a Flemish population. Journal of Hypertension, 2008, 26, 1229-1236.	0.3	16
464	Putting a spin on the ambulatory arterial stiffness index. Journal of Hypertension, 2008, 26, 1266-1267.	0.3	5
465	Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Pressure Monitoring, 2008, 13, 352-365.	0.4	48
466	Reproducibility of the ambulatory arterial stiffness index in hypertensive patients. Journal of Hypertension, 2008, 26, 1993-2000.	0.3	20
467	Isolated nocturnal hypertension and arterial stiffness in a Chinese population. Blood Pressure Monitoring, 2008, 13, 157-159.	0.4	21
468	Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular disease. Blood Pressure Monitoring, 2008, 13, 325-332.	0.4	63

#	Article	IF	CITATIONS
469	SAH gene variants revisited in the European Project On Genes in Hypertension. Journal of Hypertension, 2008, 26, 244-250.	0.3	11
470	Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. Journal of Hypertension, 2008, 26, 1328-1335.	0.3	57
471	Is blood pressure during the night more predictive of cardiovascular outcome than during the day?. Blood Pressure Monitoring, 2008, 13, 145-147.	0.4	19
472	Cadmium-Related Mortality and Long-Term Secular Trends in the Cadmium Body Burden of an Environmentally Exposed Population. Environmental Health Perspectives, 2008, 116, 1620-1628.	2.8	132
473	Bone Resorption and Environmental Exposure to Cadmium in Women: A Population Study. Environmental Health Perspectives, 2008, 116, 777-783.	2.8	180
474	Diagnostic Thresholds for Ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk. Circulation, 2007, 115, 2145-2152.	1.6	277
475	Is Isolated Nocturnal Hypertension a Novel Clinical Entity?. Hypertension, 2007, 50, 333-339.	1.3	123
476	Renin turning full circle as cardiovascular risk factor. European Heart Journal, 2007, 28, 2557-2558.	1.0	4
477	Ambulatory Arterial Stiffness Index and 24-Hour Ambulatory Pulse Pressure as Predictors of Mortality in Ohasama, Japan. Stroke, 2007, 38, 1161-1166.	1.0	128
478	Day–night blood pressure variations: mechanisms, reproducibility and clinical relevance. Journal of Hypertension, 2007, 25, 2377-2380.	0.3	38
479	Comparison of Three Measures of the Ankle-Brachial Blood Pressure Index in a General Population. Hypertension Research, 2007, 30, 555-561.	1.5	47
480	Will generic hypertension guidelines reduce the proliferation of directives?. Heart, 2007, 93, 775-777.	1.2	2
481	Angiotensin-Converting Enzyme I/D and α-Adducin Gly460Trp Polymorphisms. Hypertension, 2007, 49, 1291-1297.	1.3	59
482	Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain. Hypertension, 2007, 49, 389-400.	1.3	107
483	Context Dependency of Serum and Urinary Lithium: Implications for Measurement of Proximal Sodium Reabsorption. Hypertension, 2007, 49, e34.	1.3	2
484	Dipping Deeper Into the Ambulatory Arterial Stiffness Index. Hypertension, 2007, 50, e59-60; author reply e61-2.	1.3	14
485	On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension. Archives of Internal Medicine, 2007, 167, 1884.	4.3	124
486	Meta-analysis of blood pressure and the CYP11B2 polymorphism highlights the need for better designed studies. Journal of Hypertension, 2007, 25, 37-39.	0.3	9

#	Article	IF	Citations
487	Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. Journal of Hypertension, 2007, 25, 1554-1564.	0.3	328
488	The International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Pressure Monitoring, 2007, 12, 255-262.	0.4	130
489	???Beyond blood pressure??? means multiple risk factor intervention, not pleiotropic antihypertensive drugs. Current Opinion in Cardiology, 2007, 22, 335-343.	0.8	11
490	â^'391 C to G substitution in the regulator of G-protein signalling-2 promoter increases susceptibility to the metabolic syndrome in white European men: consistency between molecular and epidemiological studies. Journal of Hypertension, 2007, 25, 117-125.	0.3	26
491	Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Pressure Monitoring, 2007, 12, 393-395.	0.4	26
492	Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. Journal of Hypertension, 2007, 25, 2280-2285.	0.3	49
493	Anthropometric and lifestyle factors associated with white-coat, masked and sustained hypertension in a Chinese population. Journal of Hypertension, 2007, 25, 2398-2405.	0.3	36
494	Data from the Dublin outcome study. Blood Pressure Monitoring, 2007, 12, 401-403.	0.4	6
495	The association of waist circumference with ambulatory blood pressure is independent of alternative adiposity indices. Journal of Hypertension, 2007, 25, 1798-1806.	0.3	26
496	Added VALUE of an ancillary study on ambulatory blood pressure monitoring. Journal of Hypertension, 2007, 25, 513-515.	0.3	3
497	Intrafamilial Correlations of Carotid Intima–Media Thickness and Flow-Mediated Dilation in a Siberian Population. American Journal of Hypertension, 2007, 20, 248-254.	1.0	11
498	Cardiovascular Outcome in Relation to Progression to Hypertension in the Copenhagen MONICA Cohort. American Journal of Hypertension, 2007, 20, 483-491.	1.0	41
499	Renal Versus Extrarenal Activation of Vitamin D in Relation to Atherosclerosis, Arterial Stiffening, and Hypertension. American Journal of Hypertension, 2007, 20, 1007-1015.	1.0	51
500	House dust as possible route of environmental exposure to cadmium and lead in the adult general population. Environmental Research, 2007, 103, 30-37.	3.7	185
501	Sodium excretion as a modulator of genetic influence on arterial stiffness and other cardiovascular phenotypes. Artery Research, 2007, 1, 20.	0.3	0
502	Sum and substance in the Jikei Heart Study. Lancet, The, 2007, 369, 1407-1408.	6.3	14
503	Dual inhibition of the renin system by aliskiren and valsartan. Lancet, The, 2007, 370, 195-196.	6.3	35
504	Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet, The, 2007, 370, 1219-1229.	6.3	766

#	Article	IF	Citations
505	Imidapril. Drugs, 2007, 67, 1379-1382.	4.9	2
506	Circadian Variation of Blood Pressure in the Population at Large. , 2007, , 159-185.		4
507	Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncology, The, 2006, 7, 119-126.	5.1	517
508	Oral renin inhibitors. Lancet, The, 2006, 368, 1449-1456.	6.3	259
509	Reference Values in White Europeans for the Arterial Pulse Wave Recorded by Means of the SphygmoCor Device. Hypertension Research, 2006, 29, 475-483.	1.5	65
510	Reference Values for SphygmoCor Measurements in South Africans of African Ancestry. American Journal of Hypertension, 2006, 19, 40-46.	1.0	63
511	Interaction Between Body Mass Index and Alcohol Intake in Relation to Blood Pressure in HAN and SHE Chinese. American Journal of Hypertension, 2006, 19, 448-453.	1.0	25
512	Arterial Characteristics in Normotensive Offspring of Parents With or Without a History of Hypertension. American Journal of Hypertension, 2006, 19, 264-269.	1.0	35
513	Blood pressure and blood selenium: a cross-sectional and longitudinal population study. European Heart Journal, 2006, 28, 628-633.	1.0	102
514	Ambulatory arterial stiffness index predicts stroke in a general population. Journal of Hypertension, 2006, 24, 2247-2253.	0.3	129
515	Progression to hypertension in the non-hypertensive participants in the Flemish Study on Environment, Genes and Health Outcomes. Journal of Hypertension, 2006, 24, 1719-1727.	0.3	50
516	Ambulatory arterial stiffness index: determinants and outcome. Blood Pressure Monitoring, 2006, 11, 107-110.	0.4	31
517	Rationale and methodology of monitoring ambulatory blood pressure and arterial compliance in the Hypertension in the Very Elderly Trial. Blood Pressure Monitoring, 2006, 11, 3-8.	0.4	11
518	Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. Journal of Hypertension, 2006, 24, 235-242.	0.3	23
519	Ambulatory arterial stiffness index: rationale and methodology. Blood Pressure Monitoring, 2006, 11, 103-105.	0.4	69
520	Fracture risk and the use of a diuretic (indapamide sr) \hat{A}_{\pm} perindopril: a substudy of the Hypertension in the Very Elderly Trial (HYVET). Trials, 2006, 7, 33.	0.7	17
521	Antihypertensives for prevention of Alzheimer's disease. Lancet Neurology, The, 2006, 5, 466-468.	4.9	8
522	Progress in Cardiovascular Diseases. Progress in Cardiovascular Diseases, 2006, 49, 1-10.	1.6	72

#	Article	IF	CITATIONS
523	Carotid Intima-Media Thickness and Antihypertensive Treatment. Stroke, 2006, 37, 1933-1940.	1.0	253
524	Amlodipine Better Than Lisinopril?. Hypertension, 2006, 48, 359-361.	1.3	16
525	Blood Pressure Lowering for Primary and Secondary Prevention of Stroke. Hypertension, 2006, 48, 187-195.	1.3	100
526	Ambulatory Arterial Stiffness Index Derived From 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension, 2006, 47, 359-364.	1.3	307
527	Prognostic Value of Aortic Pulse Wave Velocity as Index of Arterial Stiffness in the General Population. Circulation, 2006, 113, 664-670.	1.6	1,308
528	Low-Level Environmental Exposure to Lead Unmasked as Silent Killer. Circulation, 2006, 114, 1347-1349.	1.6	62
529	Association Between Arterial Properties and Renal Sodium Handling in a General Population. Hypertension, 2006, 48, 609-615.	1.3	22
530	Ambulatory Arterial Stiffness Index as a Predictor of Cardiovascular Mortality in the Dublin Outcome Study. Hypertension, 2006, 47, 365-370.	1.3	346
531	Compared With Whom?. Hypertension, 2006, 47, 820-821.	1.3	17
532	Response to Correlating Ambulatory Blood Pressure Measurements With Arterial Stiffness: A Conceptual Inconsistency. Hypertension, 2006, 48, .	1.3	4
533	Cardiovascular and metabolic phenotypes in relation to the ADRA2B insertion/deletion polymorphism in a Chinese population. Journal of Hypertension, 2005, 23, 2201-2207.	0.3	18
534	Epistatic interaction between \hat{l}_{\pm} - and \hat{l}_{\pm} -adducin influences peripheral and central pulse pressures in white Europeans. Journal of Hypertension, 2005, 23, 961-969.	0.3	31
535	Obesity is associated with increased arterial stiffness from adolescence until old age. Journal of Hypertension, 2005, 23, 1839-1846.	0.3	235
536	Are published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The JingNing population study. Blood Pressure Monitoring, 2005, 10, 125-134.	0.4	66
537	Low-Density Lipoprotein Cholesterol and Mortality in Older People. Journal of the American Geriatrics Society, 2005, 53, 2159-2164.	1.3	66
538	Endothelial function and outdoor temperature. European Journal of Epidemiology, 2005, 20, 407-410.	2.5	56
539	Peripheral Arterial Disease and Metals in Urine and Blood. Environmental Health Perspectives, 2005, 113, A510-1; author reply A511.	2.8	10
540	Noncardiovascular Illness as Barrier to Antihypertensive Treatment. Hypertension, 2005, 46, 255-256.	1.3	5

#	Article	IF	CITATIONS
541	Self-Measurement of Blood Pressure at Home in the Management of Hypertension. Clinical Medicine and Research, 2005, 3, 19-26.	0.4	63
542	Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome. Hypertension, 2005, 45, 907-913.	1.3	253
543	Association of Blood Pressure With Genetic Variation in WNKKinases in a White European Population. Circulation, 2005, 112, 3371-3372.	1.6	8
544	Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension, 2005, 46, 386-392.	1.3	317
545	Adducin and hypertension. Pharmacogenomics, 2005, 6, 665-669.	0.6	27
546	Alcohol intake modulates the genetic association between HDL cholesterol and the PPARÎ ³ 2 Pro12Ala polymorphism. Journal of Lipid Research, 2005, 46, 913-919.	2.0	23
547	Cardiovascular Risk in Relation to α-Adducin Gly460Trp Polymorphism and Systolic Pressure. Hypertension, 2005, 46, 527-532.	1.3	48
548	OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics, 2005, 6, 755-775.	0.6	17
549	Cardiovascular Outcomes and Antihypertensive Drug Treatment in Older Women. JAMA - Journal of the American Medical Association, 2005, 293, 1588.	3.8	O
550	Adducin Polymorphism. Hypertension, 2005, 45, 331-340.	1.3	116
551	Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality. Hypertension, 2005, 46, 156-161.	1.3	1,098
552	Ouabain and Serum Sodium. Hypertension, 2005, 45, e16; author reply e16-7.	1.3	4
553	Evidence that new antihypertensives are superior to older drugs. Lancet, The, 2005, 366, 869-871.	6.3	88
554	Prevalence, Persistence, and Clinical Significance of Masked Hypertension in Youth. Hypertension, 2005, 45, 493-498.	1.3	347
555	Safety of calcium antagonists: More ACTION. American Journal of Medicine, 2005, 118, 1418-1420.	0.6	4
556	Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials. Hypertension Research, 2005, 28, 385-407.	1.5	229
557	Dragnastia Cignificance of Electropardiagraphic Voltages and Their Carial Changes in Elderly With		
	Prognostic Significance of Electrocardiographic Voltages and Their Serial Changes in Elderly With Systolic Hypertension. Hypertension, 2004, 44, 459-464.	1.3	64

#	Article	IF	CITATIONS
559	Left Ventricular Mass in Relation to Genetic Variation in Angiotensin II Receptors, Renin System Genes, and Sodium Excretion. Circulation, 2004, 110, 2644-2650.	1.6	67
560	Prevalence of hypertension, hypercholesterolemia, smoking and overweight in older Belgian adolescents. European Journal of Public Health, 2004, 14, 361-365.	0.1	13
561	Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Review of Cardiovascular Therapy, 2004, 2, 761-769.	0.6	22
562	Antihypertensive Treatment Based on Blood Pressure Measurement at Home or in the Physician's Office <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2004, 291, 955.	3.8	262
563	Meta-Analysis of effectiveness or lack thereof of Angiotensin-Converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. American Journal of Cardiology, 2004, 93, 240-243.	0.7	28
564	Renal function in relation to three candidate genes in a Chinese population. Journal of Molecular Medicine, 2004, 82, 715-722.	1.7	5
565	Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. American Journal of Hypertension, 2004, 17, 817-822.	1.0	65
566	Genetic Variation in CYP11B2 and AT1R Influences Heart Rate Variability Conditional on Sodium Excretion. Hypertension, 2004, 44, 156-162.	1.3	45
567	Telomere length and possible link to X chromosome. Lancet, The, 2004, 363, 507-510.	6.3	341
568	Convergence of atherosclerosis and Alzheimer's disease. Lancet, The, 2004, 363, 2091.	6.3	4
569	VALUE: analysis of results. Lancet, The, 2004, 364, 931.	6.3	17
570	VALUE. Journal of Hypertension, 2004, 22, 1431-1434.	0.3	9
571	Design of the Syst-Eur trial and Syst-Eur Phase 2. Journal of Hypertension, 2004, 22, 1631-1632.	0.3	0
572	Blood pressure in relation to three candidate genes in a Chinese population. Journal of Hypertension, 2004, 22, 937-944.	0.3	41
573	Association of peripheral and central arterial wave reflections with the CYP11B2 ???344C allele and sodium excretion. Journal of Hypertension, 2004, 22, 2311-2319.	0.3	34
574	Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. Journal of Hypertension, 2004, 22, 81-87.	0.3	21
575	Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. Journal of Hypertension, 2004, 22, 847-857.	0.3	172
576	Dementia and antihypertensive treatment. Current Opinion in Nephrology and Hypertension, 2004, 13, 225-230.	1.0	20

#	Article	IF	CITATIONS
577	Antihypertensive treatment based on home or office blood pressure???the THOP trial. Blood Pressure Monitoring, 2004, 9, 311-314.	0.4	29
578	Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake. Journal of Hypertension, 2004, 22, 287-295.	0.3	25
579	Ongoing trials: What should we expect after ALLHAT?. Current Hypertension Reports, 2003, 5, 340-345.	1.5	0
580	Isolated systolic hypertension and the risk of vascular disease. Current Hypertension Reports, 2003, 5, 372-379.	1.5	18
581	Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. Journal of Molecular Medicine, 2003, 81, 327-332.	1.7	53
582	Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials. Journal of Clinical Hypertension, 2003, 5, 66-75.	1.0	26
583	Essential hypertension. Lancet, The, 2003, 361, 1629-1641.	6.3	415
584	Registration of trials and protocols. Lancet, The, 2003, 362, 1009-1010.	6.3	10
585	When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. American Journal of Hypertension, 2003, 16, 87-91.	1.0	64
586	Antihypertensive treatment based on conventional or home blood pressure measurement - the thop trial. American Journal of Hypertension, 2003, 16, A63.	1.0	0
587	Salt, endogenous ouabain and blood pressure interactions in the general population. American Journal of Hypertension, 2003, 16, A170.	1.0	0
588	Î ² -Adducin polymorphisms, blood pressure, and sodium excretion in three European populations. American Journal of Hypertension, 2003, 16, 840-846.	1.0	49
589	Hypertension and Low-Level Lead Exposure: A Scientific Issue or a Matter of Faith?. Hypertension, 2003, 42, e9; author reply e9.	1.3	5
590	Blood pressure, serum total cholesterol and contraceptive pill use in 17-year-old girls. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 438-442.	3.1	21
591	Hypertension Prevalence and Stroke Mortality Across Populations. JAMA - Journal of the American Medical Association, 2003, 289, 2420.	3.8	58
592	Maternal and Paternal Influences on Left Ventricular Mass of Offspring. Hypertension, 2003, 41, 69-74.	1.3	21
593	Hypertension drug trials based on ambulatory blood pressure monitoring. Journal of Hypertension, 2003, 21, 1237-1239.	0.3	10
594	Pharmacogenomics of primary hypertension – the lessons from the past to look toward the future. Pharmacogenomics, 2003, 4, 279-296.	0.6	19

#	Article	IF	CITATIONS
595	Editorial Comment—Blood Pressure Lowering for the Secondary Prevention of Stroke: One Size Fits All?. Stroke, 2003, 34, 2590-2592.	1.0	2
596	Outcome beyond blood pressure control?. European Heart Journal, 2003, 24, 504-514.	1.0	40
597	Cardiovascular prevention and blood pressure reduction. Journal of Hypertension, 2003, 21, 1055-1076.	0.3	427
598	Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension, 2003, 21, 2409-2417.	0.3	243
599	Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. Journal of Hypertension, 2003, 21, 717-722.	0.3	109
600	ls angiogenesis a plausible hypothesis in Alzheimer's disease?. Journal of Hypertension, 2003, 21, 1426-1427.	0.3	0
601	An epidemiological study of blood pressure and metabolic phenotypes in relation to the $G\hat{I}^23$ C825T polymorphism. Journal of Hypertension, 2003, 21, 729-737.	0.3	71
602	Determinants of white-coat syndrome assessed by ambulatory blood pressure or self-measured home blood pressure. Blood Pressure Monitoring, 2003, 8, 37-40.	0.4	66
603	Blood pressure phenotypes in relation to the ??-adducin C1797T polymorphism in the European Project on Genes in Hypertension(EPOGH). Blood Pressure Monitoring, 2003, 8, 151-154.	0.4	23
604	Relation between left ventricular mass and systolic blood pressure at baseline in the APTH and THOP trials. Blood Pressure Monitoring, 2003, 8, 173-175.	0.4	9
605	What can be expected from optimal blood pressure control?. Journal of Hypertension, 2003, 21, S3-S9.	0.3	9
606	Host and environmental determinants of heart rate and heart rate variability in four European populations. Journal of Hypertension, 2003, 21, 525-535.	0.3	61
607	Salt, endogenous ouabain and blood pressure interactions in the general population. Journal of Hypertension, 2003, 21, 1475-1481.	0.3	64
608	Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. Journal of Hypertension, 2003, 21, 2251-2257.	0.3	305
609	Haematological phenotypes in relation to the C1797T \hat{l}^2 -adducin polymorphism in a Caucasian population. Clinical Science, 2003, 104, 369-376.	1.8	3
610	Haematological phenotypes in relation to the C1797T \hat{l}^2 -adducin polymorphism in a Caucasian population. Clinical Science, 2003, 104, 369.	1.8	1
611	Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases?. Acta Cardiologica, 2003, 58, 403-410.	0.3	30
612	"Sexual Maturation in Relation to Polychlorinated Aromatic Hydrocarbons": Den Hond et al.'s Response. Environmental Health Perspectives, 2003, 111, a202-a203.	2.8	0

#	Article	IF	Citations
613	Cardiovascular Risk In White-coat and Sustained Hypertensive Patients. Blood Pressure, 2002, 11, 352-356.	0.7	63
614	Relationship Between Treatment-Induced Changes in Left Ventricular Mass and Blood Pressure in Black African Hypertensive Patients. Circulation, 2002, 105, 830-836.	1.6	21
615	Peroxisome Proliferator-Activated Receptor-Â2 Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes, 2002, 51, 2653-2657.	0.3	85
616	Hormonal regulation of human adipocytes at the cross-roads between obesity and hypertension. Journal of Hypertension, 2002, 20, 839-841.	0.3	1
617	Night-time blood pressure. Journal of Hypertension, 2002, 20, 2131-2133.	0.3	46
618	Predictive Value of Clinic and Ambulatory Heart Rate for Mortality in Elderly Subjects With Systolic Hypertension. Archives of Internal Medicine, 2002, 162, 2313.	4.3	254
619	The Prevention of Dementia With Antihypertensive Treatment <subtitle>New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study</subtitle> . Archives of Internal Medicine, 2002, 162, 2046.	4.3	784
620	Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension: Results from the Syst-Eur Trial. Journal of the American Society of Nephrology: JASN, 2002, 13, 2213-2222.	3.0	172
621	Conventional Therapy and Newer Drug Classes for Cardiovascular Protection in Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, S208-S215.	3.0	11
622	Subgroup analysis of the NORDIL trial. Journal of Hypertension, 2002, 20, 1085-1087.	0.3	0
623	Characteristics of conventional blood pressure in studies on the predictive power of ambulatory blood pressure. Blood Pressure Monitoring, 2002, 7, 33-36.	0.4	9
624	Carotid and femoral intima–media thickness in relation to three candidate genes in a Caucasian population. Journal of Hypertension, 2002, 20, 1551-1561.	0.3	58
625	Comparison of conventional and automated blood pressure measurements: interim analysis of the THOP trial. Blood Pressure Monitoring, 2002, 7, 61-62.	0.4	18
626	Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Pressure Monitoring, 2002, 7, 169-177.	0.4	56
627	Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Pressure Monitoring, 2002, 7, 215-224.	0.4	109
628	Withdrawal from treatment in the Syst-Eur Trial. Journal of Hypertension, 2002, 20, 339-346.	0.3	9
629	Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial. Journal of Hypertension, 2002, 20, 2069-2079.	0.3	25
630	Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. Journal of Hypertension, 2002, 20, 145-151.	0.3	136

#	Article	IF	Citations
631	If only cardiologists did properly measure blood pressure. Journal of the American College of Cardiology, 2002, 40, 2201-2203.	1.2	33
632	Risk reduction for stroke and coronary events. Lancet, The, 2002, 359, 1250-1251.	6.3	2
633	How to use home blood pressure monitors in clinical practice. American Journal of Hypertension, 2002, 15, 93-96.	1.0	24
634	Clinical applications of arterial stiffness; definitions and reference values. American Journal of Hypertension, 2002, 15, 426-444.	1.0	953
635	Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, A27.	1.0	0
636	Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. American Journal of Hypertension, 2002, 15, S85-S93.	1.0	31
637	Ambulatory pulse pressure aspredictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, 835-843.	1.0	93
638	Host and environmental determinants of polychlorinated aromatic hydrocarbons in serum of adolescents Environmental Health Perspectives, 2002, 110, 583-589.	2.8	42
639	Immunologic biomarkers in relation to exposure markers of PCBs and dioxins in Flemish adolescents (Belgium) Environmental Health Perspectives, 2002, 110, 595-600.	2.8	91
640	Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek's hypothesis revisited Environmental Health Perspectives, 2002, 110, 771-776.	2.8	204
641	Association between hypertension and variation in the \hat{l}_{\pm} - and \hat{l}^{2} -adducin genes in a white population. Kidney International, 2002, 62, 2152-2159.	2.6	64
642	Should high-normal blood pressure be treated?. Journal of Hypertension, 2002, 20, 1028-1030.	0.3	2
643	Are the benefits of antihypertensive therapy only due to blood pressure reduction?. Journal of Hypertension, 2002, 20, 2096-2097.	0.3	0
644	The pulse pressure-to-stroke index ratio predicts cardiovascular events and death in uncomplicated hypertension. Journal of the American College of Cardiology, 2001, 38, 227-231.	1.2	59
645	Improved Outcomes with Antihypertensive Medication in the Elderly with Isolated Systolic Hypertension. Drugs and Aging, 2001, 18, 345-353.	1.3	6
646	Benefits of antihypertensive drug treatment in elderly patients with isolated systolic hypertension. Netherlands Journal of Medicine, 2001, 58, 248-254.	0.6	8
647	A plea for harmonising guidelines. International Journal of Cardiology, 2001, 79, 129-132.	0.8	1
648	Renal function in relation to three candidate genes. American Journal of Kidney Diseases, 2001, 38, 1158-1168.	2.1	50

#	Article	IF	Citations
649	Prevalence of hypertension and other cardiovascular risk factors in 17-18-year old Belgian adolescents. American Journal of Hypertension, 2001, 14, A244.	1.0	0
650	Dementia and statins. Lancet, The, 2001, 357, 880.	6.3	9
651	Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet, The, 2001, 357, 1660-1669.	6.3	183
652	Blood-pressure lowering for the secondary prevention of stroke. Lancet, The, 2001, 358, 1026-1027.	6.3	49
653	Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, The, 2001, 358, 1305-1315.	6.3	892
654	Delayed sexual development in adolescents. Lancet, The, 2001, 358, 1817.	6.3	2
655	The lowering of blood pressure after stroke. Lancet, The, 2001, 358, 1995-1996.	6.3	4
656	Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Journal of Hypertension, 2001, 19, 511-519.	0.3	113
657	Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. Journal of Hypertension, 2001, 19, 1037-1044.	0.3	323
658	Ambulatory and conventional pulse pressures and mean pressures as determinants of the Sokolow-Lyon ECG voltage index in older patients with systolic hypertension. Blood Pressure Monitoring, 2001, 6, 197-202.	0.4	4
659	Relationships of heart rate and heart rate variability with conventional and ambulatory blood pressure in the population. Journal of Hypertension, 2001, 19, 389-397.	0.3	32
660	Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. Journal of Hypertension, 2001, 19, 1349-1358.	0.3	205
661	Risk and benefit of treatment of isolated systolic hypertension in the elderly: evidence from the Systolic Hypertension in Europe Trial. Current Opinion in Cardiology, 2001, 16, 342-348.	0.8	18
662	Risks of smoking in treated and untreated older Chinese patients with isolated systolic hypertension. Journal of Hypertension, 2001, 19, 187-192.	0.3	11
663	Antihypertensive drug therapy in older patients. Current Opinion in Nephrology and Hypertension, 2001, 10, 263-269.	1.0	5
664	Task Force II: Blood pressure measurement and cardiovacular outcome. Blood Pressure Monitoring, 2001, 6, 355-370.	0.4	170
665	Blood Pressure, Cognitive Functions, and Prevention of Dementias in Older Patients With Hypertension. Archives of Internal Medicine, 2001, 161, 152.	4.3	136
666	The benefit of treating isolated systolic hypertension. Current Hypertension Reports, 2001, 3, 333-339.	1.5	15

#	Article	IF	Citations
667	Does B-mode common carotid artery intima-media thickness differ from M-model?. Ultrasound in Medicine and Biology, 2001, 27, 1333-1336.	0.7	24
668	How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 298.	1.5	12
669	Prognostic Significance of Serum Creatinine and Uric Acid in Older Chinese Patients With Isolated Systolic Hypertension. Hypertension, 2001, 37, 1069-1074.	1.3	145
670	Efficacy of Different Drug Classes Used to Initiate Antihypertensive Treatment in Black Subjects. Archives of Internal Medicine, 2001, 161, 965.	4.3	84
671	Carotid and Femoral Artery Stiffness in Relation to Three Candidate Genes in a White Population. Hypertension, 2001, 38, 1190-1197.	1.3	84
672	Circadian Variation of the Blood Pressure in the Population at Large. , 2001, , 139-158.		1
673	Ambulatory blood pressure of adults in Novosibirsk, Russia: interim report on a population study. Blood Pressure Monitoring, 2000, 5, 291-296.	0.4	31
674	Genetic polymorphisms in the renin–angiotensin system: relevance for susceptibility to cardiovascular disease. European Journal of Pharmacology, 2000, 410, 289-302.	1.7	142
675	Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovascular Drugs and Therapy, 2000, 14, 49-53.	1.3	18
676	Ambulatory Blood Pressure: Normality and Comparison With Other Measurements. Hypertension, 2000, 35, E8.	1.3	15
677	Critical appraisal of the JNC VI, WHO/ISH and BHS guidelines for essential hypertension. Expert Opinion on Pharmacotherapy, 2000, 1, 675-682.	0.9	15
678	Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension. Circulation, 2000, 102, 1139-1144.	1.6	271
679	Pulse Pressure Not Mean Pressure Determines Cardiovascular Risk in Older Hypertensive Patients. Archives of Internal Medicine, 2000, 160, 1085.	4.3	502
680	Effect of Age on Brachial Artery Wall Properties Differs From the Aorta and Is Gender Dependent. Hypertension, 2000, 35, 637-642.	1.3	344
681	Blood Pressure–Measuring Devices. Hypertension, 2000, 35, 1037-1037.	1.3	12
682	What does STOP-2 tell us about management of hypertension?. Lancet, The, 2000, 355, 651.	6.3	1
683	Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet, The, 2000, 355, 865-872.	6.3	1,136
684	Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension. New England Journal of Medicine, 1999, 340, 677-684.	13.9	911

#	Article	IF	Citations
685	Predicting Cardiovascular Risk Using Conventional vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension. JAMA - Journal of the American Medical Association, 1999, 282, 539.	3.8	1,369
686	Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. Hypertension, 1999, 33, 1476-1477.	1.3	46
687	Treatment of diabetic patients with hypertension. Current Hypertension Reports, 1999, 1, 225-231.	1.5	10
688	Clinical trials in isolated systolic hypertension. Current Hypertension Reports, 1999, 1, 387-393.	1.5	5
689	Implications of the Systolic Hypertension in China Trial. Clinical and Experimental Hypertension, 1999, 21, 499-505.	0.5	13
690	Treatment of isolated systolic hypertension in the elderly: evidence from three clinical trials. European Journal of Internal Medicine, 1999, 10, 82-87.	1.0	2
691	Prevention of dementia: Syst-Eur trial. Lancet, The, 1999, 353, 236-237.	6.3	16
692	What is hypertension?. Lancet, The, 1999, 354, 594.	6.3	9
693	Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study. Lancet, The, 1999, 353, 1140-1144.	6.3	364
694	What is "hypertension�. Lancet, The, 1999, 353, 1541-1543.	6.3	32
695	Influence of demographic, anthropometric and lifestyle characteristics on heart rate and its variability in the population. Journal of Hypertension, 1999, 17, 1589-1599.	0.3	82
696	M235T angiotensinogen gene polymorphism and cardiovascular renal risk. Journal of Hypertension, 1999, 17, 9-17.	0.3	186
697	The International Database of Self-Recorded Blood Pressures in normotensive and untreated hypertensive subjects. Blood Pressure Monitoring, 1999, 4, 77-86.	0.4	66
698	Leuven Consensus Conference on Ambulatory Blood Pressure Monitoring in commemoration of Professor Dr A. Amery (†2 November 1994) 23–25 September 1999. Blood Pressure Monitoring, 1999, 4, 277-278.	0.4	1
699	Task Force IV: Clinical use of ambulatory blood pressure monitoring. Blood Pressure Monitoring, 1999, 4, 319-331.	0.4	76
700	Treatment of isolated systolic hypertension in the elderly: further evidence from the Systolic Hypertension in Europe (Syst-Eur) trial. American Journal of Cardiology, 1998, 82, 20-22.	0.7	63
701	Hypertension Optimal Treatment (HOT) trial. Lancet, The, 1998, 352, 573.	6.3	6
702	Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, The, 1998, 352, 1347-1351.	6.3	1,336

#	Article	IF	Citations
703	Subgroup and Per-Protocol Analysis of the Randomized European Trial on Isolated Systolic Hypertension in the Elderly. Archives of Internal Medicine, 1998, 158, 1681.	4.3	123
704	Calcium Channel Blockade and Cardiovascular Prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension, 1998, 32, 410-416.	1.3	66
705	Detection of Cerebral Aging,an Absolute Need: Predictive Valueof Cognitive Status. European Neurology, 1998, 39, 2-6.	0.6	12
706	ANTIHYPERTENSIVE DRUGS AND COGNITIVE FUNCTION IN OLDER PEOPLE. Journal of the American Geriatrics Society, 1998, 46, 791-791.	1.3	1
707	Reference Values for Self-recorded Blood Pressure. Archives of Internal Medicine, 1998, 158, 481.	4.3	120
708	Correlates of cognitive status of old patients with isolated systolic hypertension. Journal of Hypertension, 1998, 16, 963-969.	0.3	73
709	Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Journal of Hypertension, 1998, 16, 1823-1829.	0.3	622
710	Antihypertensive Treatment Based on Conventional or Ambulatory Blood Pressure Measurement. JAMA - Journal of the American Medical Association, 1997, 278, 1065.	3.8	164
711	Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 401-422.	1.5	66
712	Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. Journal of Hypertension, 1997, 15, 1493-1502.	0.3	64
713	The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. Journal of Hypertension, 1997, 15, 1579-1592.	0.3	336
714	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, The, 1997, 350, 757-764.	6.3	2,841
715	Treatment of hypertension in elderly patients. Lancet, The, 1997, 350, 1634.	6.3	0
716	Prediction of Cardiac Structure and Function by Repeated Clinic and Ambulatory Blood Pressure. Hypertension, 1997, 29, 22-29.	1.3	110
717	Nocturnal Blood Pressure Fall on Ambulatory Monitoring in a Large International Database. Hypertension, 1997, 29, 30-39.	1.3	269
718	Determining the Trough-to-Peak Ratio in Parallel-Group Trials. Hypertension, 1997, 29, 659-667.	1.3	20
719	Ambulatory Blood Pressure Monitoring in Clinical Trials. Annals of the New York Academy of Sciences, 1996, 783, 295-303.	1.8	5
720	Potential adverse effects of blood pressure loweringâ€"J-curve revisited. Lancet, The, 1996, 348, 696-697.	6.3	28

#	Article	IF	Citations
721	Advantages and disadvantages of the meta-analysis approach. Journal of Hypertension, 1996, 14, S9-S13.	0.3	98
722	Associations of orthostatic blood pressure fall in older patients with isolated systolic hypertension. Journal of Hypertension, 1996, 14, 943???950.	0.3	15
723	Participation rate in the Belgian population study on ambulatory blood pressure monitoring. Journal of Hypertension, 1996, 14, 1257.	0.3	0
724	Life Style as a Blood Pressure Determinant. Journal of the Royal Society of Medicine, 1996, 89, 484-489.	1.1	9
725	Public health implications of environmental exposure to cadmium and lead: an overview of epidemiological studies in Belgium. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 26-41.	1.5	68
726	Lead Exposure and Conventional and Ambulatory Blood Pressure. JAMA - Journal of the American Medical Association, 1996, 275, 1563.	3.8	53
727	Hypertension and Lead Exposure. JAMA - Journal of the American Medical Association, 1996, 276, 1037.	3.8	2
728	Ambulatory Monitoring Uncorrected for Placebo Overestimates Long-term Antihypertensive Action. Hypertension, 1996, 27, 414-420.	1.3	22
729	Prognostic Value of Invasive Hemodynamic Measurements at Rest and During Exercise in Hypertensive Men. Hypertension, 1996, 28, 31-36.	1.3	79
730	The relationships between left ventricular mass and daytime and night-time blood pressures: a meta-analysis of comparative studies. Journal of Hypertension, 1995, 13, 823-829.	0.3	95
731	Trough-To-Peak Versus Surface Ratio in the Assessment of Antihypertensive Agents. Blood Pressure, 1995, 4, 350-357.	0.7	12
732	A Consensus View on the Technique of Ambulatory Blood Pressure Monitoring. Hypertension, 1995, 26, 912-918.	1.3	86
733	The Trough-to-Peak Ratio as an Instrument to Evaluate Antihypertensive Drugs. Hypertension, 1995, 26, 942-949.	1.3	22
734	Psycho-Emotional Stress and Salt Intake May Interact to Raise Blood Pressure. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 45-51.	3.1	7
735	Hypertension Caused by Low-Level Lead Exposure: Myth or Fact?. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 87-97.	3.1	18
736	Ambulatory Blood Pressure and Blood Pressure Measured at Home. Journal of Cardiovascular Pharmacology, 1994, 23, S5-S11.	0.8	48
737	Life Style as a Determinant of Blood Pressure in the General Population. American Journal of Hypertension, 1994, 7, 685-694.	1.0	46
738	Psycho-emotional stress and salt intake may interact to raise blood pressure. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 45-51.	1.5	11

#	Article	IF	CITATIONS
739	Is a positive association between lead exposure and blood pressure supported by animal experiments?. Current Opinion in Nephrology and Hypertension, 1994, 3, 257-263.	1.0	16
740	Efficacy of antihypertensive drugs given once a day. Journal of Hypertension, 1994, 12, 107???116.	0.3	8
741	Ambulatory blood pressure in normotensive and hypertensive subjects. Journal of Hypertension, 1994, 12, S13???S22.	0.3	64
742	Hypertension caused by low-level lead exposure: myth or fact?. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 87-97.	1.5	53
743	Fourier Analysis of Blood Pressure Profiles. American Journal of Hypertension, 1993, 6, 184S-187S.	1.0	34
744	Short report: Low-level lead exposure does not increase the blood pressure in the general population. Journal of Hypertension, 1993, 11, 589-593.	0.3	19
745	Short report. Journal of Hypertension, 1993, 11, 1289???1298.	0.3	25
746	The relationship between blood pressure and sodium and potassium excretion during the day and at night. Journal of Hypertension, 1993, 11, 443-447.	0.3	77
747	Impairment of Renal Function with Increasing Blood Lead Concentrations in the General Population. New England Journal of Medicine, 1992, 327, 151-156.	13.9	228
748	Impact of Environmental Cadmium Pollution on Cadmium Exposure and Body Burden. Archives of Environmental Health, 1992, 47, 347-353.	0.4	66
749	Transfer of cadmium from a sandy acidic soil to man: A population study. Environmental Research, 1992, 58, 25-34.	3.7	33
750	Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. American Journal of Cardiology, 1991, 67, 723-727.	0.7	206